Overcoming Funding Barriers for Radiopharmaceutical Innovation through Looking at Scientific & Commercial Considerations

• Analyzing the interplay between regulatory uncertainty, clinical complexity, and investor risk perception
• Prioritizing scientific strategies that improve translational success and attract sustainable funding
• Demonstrating the value proposition of next-generation TRPs to stakeholders, including patient advocates, payers, and industry partners

Speakers:

Kemp Dolliver

Director of Research

Brookline Capital Markets